1. Home
  2. PZG vs TENX Comparison

PZG vs TENX Comparison

Compare PZG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

SELL

Current Price

$0.94

Market Cap

84.0M

ML Signal

SELL

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

SELL

Current Price

$1.48

Market Cap

73.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PZG
TENX
Founded
1992
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.0M
73.8M
IPO Year
2015
2001

Fundamental Metrics

Financial Performance
Metric
PZG
TENX
Price
$0.94
$1.48
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $10.29
AVG Volume (30 Days)
265.9K
★ 1.4M
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $330,259.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.88
$1.31
52 Week High
$2.70
$19.40

Technical Indicators

Market Signals
Indicator
PZG
TENX
Relative Strength Index (RSI) 41.67 34.99
Support Level $0.88 $1.34
Resistance Level $1.06 $2.01
Average True Range (ATR) 0.07 0.14
MACD 0.01 0.01
Stochastic Oscillator 37.86 4.46

Price Performance

Historical Comparison
PZG
TENX

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold and Bald Peak Project.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: